Survodutide
A weight-loss peptide working on two targets, in development by Boehringer Ingelheim for obesity and liver disease.
Also listed as BI 456906.
Peptide Compare tracked 14 vendors selling Survodutide on 9 Oct 2026. The cheapest in-stock 10 mg vial is $7.20 per mg at Good Science after its 20% coupon, 19% under the $8.90 median. Prices are scraped from vendor sites; trust scores come from Finnrick blind tests.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
Best value right now · 10 mg
GS
Good Science
IN STOCKUNTESTED
Per mg19% under the $8.90 median
Vial price10 mg · verified Oct 9
Avg per mg · 10 mg
$9.96−17.6%
Ranged $9.93 – $12.08 across 14 vendorsCompare 9 vendors · 10 mg
Across all sizes, verified in-stock listings run $74.99 to $225.00 from 7 vendors.
VendorStock
09
Umbrella LabsUNTESTED · OUT
$13.00$129.99
Showing 8 of 9 vendors · 1 more from $13.00/mg
Survodutide prices verified Oct 9, 2026
$7.20/mgGood Science · $72.00
Buy best priceSee how Survodutide moved against the rest of the catalogue in the Peptide Price Index: median price per mg now versus 30 and 90 days ago, every tracked peptide, with a CSV.
Survodutide price by vial size
| Vial size | Lowest per mg | Vial price | Vendor |
|---|---|---|---|
| 5 mg | $15.00 | $75.00 | Polaris Peptides1 vendor carries it |
| 10 mg | $7.20 | $72.00 | Good Science9 vendors carry it |
| Other | $37.50 | $225.00 | Paramount Peptides4 vendors carry it |
Verified 9 Oct 2026. Lowest figures are in-stock listings checked within the last week, with any coupon applied; a size with none says so.
Price movement · 30 days
0%median per mg, all sizes
Cheapest ever recorded: $7.50/mg on Aug 7. Today matches it.See our top-ranked Survodutide vendors
Ranked by Finnrick trust score, independent lab testing, and price.
Compare Survodutide head-to-head
- Survodutide vs Retatrutide
- Survodutide vs Tirzepatide
- Survodutide vs Semaglutide
- Survodutide vs Cagrilintide
- Survodutide vs AOD-9604
- Survodutide vs 5-Amino-1MQ
Quick Summary
A dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim, studied for obesity and for metabolic dysfunction-associated steatohepatitis. Available from 14 vendors, priced from $74.99 to $240.00.
Research: The confirmatory Phase 3, SYNCHRONIZE (2026, PMID 42253238), reports mean weight losses at week 76 of 12.2% at 3.6 mg and 13.0% at 6.0 mg against 5.4% on placebo. The 18.7% figure that used to appear here could not be located anywhere in the Phase 2 paper (Le Roux et al, Lancet Diabetes Endocrinol 2024, PMID 38330987, n=387, 46 weeks), whose planned-treatment result at 4.8 mg was 14.9% (95% CI 13.0 to 16.9) against 2.8% on placebo. In the separate MASH Phase 2 (Sanyal et al, NEJM 2024, PMID 38847460), 62% reached MASH resolution without worsening of fibrosis against 14% on placebo.
Side effects: No per-arm adverse event rates were verified for this page
Phase 3Boehringer Ingelheim SYNCHRONIZE program. Not approved in any jurisdiction.
- 12 of 14 vendors currently have it in stock
- Highest-rated vendor: Peptidology (7.6 Finnrick score)
- Most common vial size: 10mg
- Category: Weight Loss (GLP-1) — GLP-1 receptor agonists for weight management
Get Survodutide price alerts
Join the list — price-drop alerts for this peptide are in the works and you'll be first on them.